ABBVAbbVieRunning, no new patients
IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia
Acute Myeloid Leukemia
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 218 (final count)
- Started
- Nov 6, 2019
- Main results expected
- Feb 2027
- Fully finished
- Feb 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Safety and Tolerability
Measured over: approximately 3 years
Preliminary antileukemia activity
Measured over: approximately 20 months
Minimal Residual Disease Levels
Measured over: approximately 18 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT04086264 · record last updated 2025-08-14 · checked 2026-11-09 15:47 UTC